Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Turk JR, Deaton AM, Yin J, Stolina M, Felx M, Boyd G, Bienvenu JG, Varela A, Guillot M, Holdsworth G, Wolfreys A, Dwyer D, Kumar SV, de Koning EM, Qu Y, Engwall M, Locher K, Ward LD, Glaus C, He YD, Boyce RW.
Turk JR, et al. Among authors: guillot m.
Regul Toxicol Pharmacol. 2020 Aug;115:104697. doi: 10.1016/j.yrtph.2020.104697. Epub 2020 Jun 23.
Regul Toxicol Pharmacol. 2020.
PMID: 32590049
Free article.